GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine
- PMID: 40601607
- PMCID: PMC12221084
- DOI: 10.1371/journal.pone.0326210
GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine
Abstract
Background: The injectable glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drugs are commonly used for weight loss among reproductive-aged women but the perception of their impact on fertility is not clear among the public.
Objectives: The purpose of this review was to compare scientific literature to social media discourse and online search pertaining to the potential impact of GLP-1 RAs on female fertility.
Methods: Group 1 included 3 social media platforms, each of which required a different data collection method. For Reddit, VADER (Communalytic ®) was used as a sentiment analyzer and for Twitter and TikTok, we performed a manual search for posts and scored them using an objective internal scale. Group 2 included the online search engine Google Trends. Group 3 consisted of medical literature search by PubMed. All sentiments of posts/comments/articles were graded as: "Positive, Neutral, or Negative" and compared among groups.
Results: In Groups 1 and 2, scores showed a significantly more Positive than Neutral, and more Neutral than Negative sentiments. In Group 3, among the 52 original studies found on PubMed in women with polycystic ovary syndrome (PCOS), they all had Positive sentiments. In Groups 1, 2, and 3, there was a strong positive correlation among all sentiments (r2 = 0.83). Even though all 3 social media platforms had the majority of posts with a Positive sentiment and correlated with Google Trends posts and with PubMed studies in women with PCOS (r2 = 0.74), there was a lack of PubMed studies pertaining to the effect of GLP-1 RA in women without PCOS.
Conclusion: The Positive sentiments among women without PCOS is not justified by evidence-based medicine and there is a clear need for studies pertaining to this topic.
Copyright: © 2025 Merhi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
NO authors have competing interests
Similar articles
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. Cochrane Database Syst Rev. 2022. PMID: 36165742 Free PMC article.
-
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
References
-
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56. - PubMed
-
- Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:839–48. - PubMed
-
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical